Knowledge hub

3.13 MB
zip

Materials for Health education on VL used in South Sudan (IEC/BCC)

29 Mar 2019
Training material
Health education
South Sudan

Determinants for progression from asymptomatic infection to symptomatic visceral leishmaniasis: A cohort study

A prospective study in two high VL incidence areas of Muzaffarpur district, Bihar State, India from 2008–2015 was conducted with resident subjects. The study aimed at  identifying markers for progression from L. donovani infection to clinical Visceral Leishmaniasis (VL). Both high DAT and/or rK39 titers were associated with progression to disease and qPCR was identified as an additional predictor. The authors also recommend that asymptomatic individuals with low predictive values are carefully observed for at least 6 months after testing.

28 Mar 2019
Academic paper
Improving surveillance, Case management
India
1.85 MB
pdf

National Guideline on Kala-azar Elimination Program for Nepal, 2019

The 2019 new and updated National Guideline for Kala-azar Elimination Programme for Nepal. It has been devleoped by the Epidemiology and Disease Control Division (EDCD) of the Ministry of Health and Population, Government of Nepal. For more information on the National program, see http://www.edcd.gov.np/section/kala-azar-elimination-program.

26 Mar 2019
Policy paper
Nepal
1.85 MB
pdf

National Guideline on Kala-azar Elimination Program for Nepal, (Updated) 2019

The 2019 new and updated National Guideline for Kala-azar Elimination Programme for Nepal. It has been devleoped by the Epidemiology and Disease Control Division (EDCD) of the Ministry of Health and Population, Government of Nepal. For more information on the National program, see http://www.edcd.gov.np/section/kala-azar-elimination-program.

26 Mar 2019
Policy paper
Nepal

Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis

A systematic review of 15 studies examining VL treatment outcomes at end of treatment and at 6 months follow-up in Ethiopia.

25 Mar 2019
Academic paper
Case management
Ethiopia

Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia

A prospective cohort study conducted in Northwest Ethiopia from August 2014 to August 2017 examined long-term treatment outcomes of visceral leishmaniasis (VL) patients with HIV co-infection, who are at high rate of relapse. HIV-VL patients were followed for up to 12 months with their CD4 counts were monitored. The study concludes that "patients with relapsed VL are at higher risk for subsequent relapse and should be considered a priority for secondary prophylaxis, irrespective of their CD4 count".

13 Mar 2019
Academic paper
Case management
Ethiopia

Visceral Leishmaniasis: Recent Advances in Diagnostics and Treatment Regimens

Review of the current diagnostic and treatment tools used for the management of visceral leishmaniasis.

8 Mar 2019
Academic paper
Case management

Eliminating visceral leishmaniasis in South Asia: the road ahead

This paper reviews recent progress for VL control measures and identifies priority areas to reach the 2020 VL elimination target in the South Asian region.

5 Mar 2019
Academic paper
India, Bangladesh, Nepal

Barriers of Visceral Leishmaniasis reporting and surveillance in Nepal: comparison of governmental VL‐program districts with non‐program districts

A cross‐sectional mixed‐method study on populations from districts targeted by the national VL programme and non‐program districts. The researchers describe delays to health-seeking, to diagnosis and to treatment in the two populations and identify barriers to access in Nepal.

13 Feb 2019
Academic paper
Improving surveillance
Nepal

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia

This study reports on the results of a randomized trial of AmBisome - miltefosine combination therapy and AmBisome monotherapy in Ethiopian HIV-VL co-patients, in order to assess dose efficacy at the end of treatment.
 
The authors conclude that "the extended treatment strategy with the combination regimen showed the highest documented efficacy in HIV-VL patients; these results support a recommendation of this regimen as first-line treatment strategy for HIV-VL patients in eastern Africa".
31 Jan 2019
Academic paper
Case management
Ethiopia

Pages